

**Ohio Department of Job and Family Services (ODJFS)
Drug Utilization Review (DUR) Board
Quarterly Meeting
November 15, 2011**

The quarterly meeting of the ODJFS DUR Board was called to order at 12:06 PM in room West B&C of the 31st floor of the Riffe Building, 77 S. High St. Columbus, Ohio. Kevin Mitchell, RPh presided. The following Board members were present:

David Brookover, RPh
Thomas Gretter, MD
Robert Kubasak, RPh
J. Layne Moore, MD
Lenard Presutti, DO
Donald Sullivan, RPh, PhD

Also present were Jill Griffith, RPh, DUR Director, and from the University of Cincinnati College of Pharmacy, Pam Heaton RPh, PhD and Bob Cluxton, RPh, PhD. Approximately seven observers were present representing pharmaceutical manufacturers and one pharmacy student. Michael Farrell, MD and Margaret Scott, RPh, DUR Administrator, were absent.

Reading, Correction & Approval of Previous Minutes:

The May 10th, 2011, DUR Board minutes were approved. (1st T. Gretter, 2nd R. Kubasak).

DUR Committee Report:

J. Griffith gave the DUR committee report.

The May and June 2011 DUR Committee worked on the 2010 Doctor Shopping re-review, 381 profiles of patients taking three or more prescriptions from at least three different prescribers for carisoprodol, tramadol or any schedule two to five drug during any 45 day period within the study window. The committee found 5,718 prescriptions for Dr. Shopping drugs between January and March 2010. Upon re review, the committee found 2,914 prescriptions for Dr. Shopping drugs between January and March 2011. Numerically, the difference is 2,804 prescriptions. A 49 percent decrease in the number of controlled prescriptions for the same patient group one year later. Dr. Gretter asked about reasons for the decline. One reason may be because pill mills have been shut down. K. Mitchell stated that checking the Ohio Automated RX Reporting System (OARRS) likely contributed to the decline of controlled substance prescriptions as well. P. Heaton added that physician feedback for this type of review is positive and physicians appreciate the information.

The statin letters were also mailed during the month of May. This letter targeted physicians with two or more patients post myocardial infarction (MI) who were not

taking a statin. 564 response forms of the total 1,249 were returned. 190 physicians felt the current treatment was appropriate, 78 responded that their patients had with upcoming appointments to discuss therapy and 45 intended to change therapy.

No DUR Committee meetings were held during the months of July, August, September and October.

The DUR Committee met in November and re-reviewed the duplicate long-acting narcotic mailing August 2010. The committee determined that of 210 patients on at least two long acting narcotic products concurrently: 93 (44 percent) decreased to one or no long acting products, 89 patients had no change (42.5 percent) in therapy, there was one death and 27 patients left the benefit (13 percent).

The December and January DUR Committee will re-review the duplicate long acting stimulant mailing from November 2010.

Health Plan Policy:

Ms. Scott was unable to attend the meeting. No health plan policy update was given.

Unfinished Business:

J. Griffith requested the Board consider ideas for the 2012 review calendar. Testing should be completed on the new RETRODUR computer system in time to update and mail the HIV Compliance letters in February.

The P&T Committee asked the DUR Committee to look at utilization for several new drugs including the ADHD drugs Kapvay (clonidine ER) and Intuniv (guanfacine ER); as well as the cardiovascular product Effient (prasugrel) to see if the use thus far is felt to be appropriate. The DUR Committee will tentatively plan to look at this in February.

The simvastatin label has been updated and there are now very clear drug interactions/contraindications and new dose recommendations. The 80 mg strength should be used only in those already taking this dose for 12 months or more without evidence of muscle injury. Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug. The University of Cincinnati is currently working to let us know the scope of patients on the contraindicated drug combinations and new starts on the simvastatin 80 mg strength. D. Sullivan asked about the generic availability of atorvastatin and would this be an authorized generic.

The Board approved these review topics.

D. Sullivan suggested the committee consider reviewing Suboxone and Subutex again this year. J. Griffith agreed. She would like the DUR committee to look at concurrent controlled substance use with Suboxone and Subutex in addition to duplicative long acting narcotics and stimulants yearly as we do with Dr. Shopping.

New Business:

J. Griffith announced that the DUR annual report submitted to CMS will be submitted late this year.

David Brookover, RPh was elected Chair and Lenard Presutti, DO elected co-chair.

Michael Farrell, MD; Lenard Presutti, DO; Robert Kubasak, RPh and David Brookover, RPh all have expiring terms and have been contacted about reappointments.

Announcements:

The first and second quarter DUR Board meetings are scheduled for noon on Tuesday, February 21st and Tuesday, May 8th. Location to be announced.

R. Kubasak discussed managed care plan, claims processing and compounding difficulties his pharmacy experienced with the managed care carve-in transition. L. Presutti stated his small practice made 50 prior authorization calls. K. Mitchell expressed concerns regarding flu shot reimbursement. D. Brookover felt the carve-in went rather smoothly.

Adjournment:

K. Mitchell adjourned the meeting at 12:45 PM.

Respectfully submitted:

Jill R.K. Griffith B.S., Pharm.D., DUR Program Director